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Tacrolimus (FK5061 is now an accepted primary im-
munosuppressive agent after solid-organ transplantation' 
(\ -13). It has both short-term and long-term ad\'antages 
o\,er conventional drugs: it is associated with less fre-
quent rejection. hypertension. and hypercholesterolemia 
compared with cyclosporine. It also has been used to 
sal\'age allografts with acute cellular rejection not re-
sponding to cyclosporine and OKT3 (-l-6.8.l·U5). 
Cyclosporine and tacrolimus are structurally unrelated 
compounds and bind to different cytosolic proteins in 
target cells. Nonetheless. both dru!!s have a closelv re-
lated mechanism of action that is ;elated primarily' to a 
block in the transcription of interleukin-2 mRNA (16). 
This basic similarity in the mechanism of action is par-
alleled by an overlap in their toxicity profile: both drugs 
are toxic principally to the kidneys. central nervous sys-
tem. gastrointestinal tract. and islets of Langerhans. The 
overall incidence of ad\'erse e\-ents depends on dosage 
and clinical experience but appears to be comparable for 
both agents (7.11.17 l. T \\0 multicenter trials report ta-
crolimus to have higher nephrotoxicity, neurotoxicity. 
and diabetogeniciry (18.19). but these conclusions have 
been criticized (20). 
The following re\'iew focuses on the nephrotoxic ac-
tions of tacrolimus with particular reference to the asso-
ciated histopathological changes seen in the allograft 
kidney. Throughout the discussion. emphasis is on how 
similar these changes are to those reported with cyclo-
sporine therapy. 
Received January I·t 199~: gcK:-~pted January 15. 1997 
Address correspondenct' ll' Dr. marrnie~t S. Randhawa. Assistant 
Professor. Division of Trampi:mt marh~fEl!!yIK C903.1. University of 
Pittsburgh Medical Center. Pm,burgh. P:\ is::13. U.S.A. . 
265 
MECHANISMS OF 
TACROLnmS NEPHROTOXICITY 
The mechanism of immunosuppression mediated by 
cyclosporine and tacrolimus has been investigated inten-
sively. It is belie\'ed that these drugs first must bind to 
their respective intracellular immunophilin receptors. 
particularly cyclophilin A and FK506 binding protein 11 
(FKBPI2). The immunophilin drug complex inactivates 
a phosphatase called ca\Cineurin, which acts on addi-
tional target proteins that ultimately prevent the nuclear 
import of nuclear factor of activated T cells (NF-A T). a 
factor known to mediate the expression of several T-cell-
activation genes. The resultant effects on the transcrip-
tion and mRNA degradation of several cytokine genes 
have been described. of which the most important is 
interleukin-2, because this molecule plays a critical role 
in T-cell proliferation associated with alloimmune reac-
tions (21). 
The molecular basis of cyclosporine and tacrolimus 
nephrotoxicity is less well understood. but there is evi-
dence that it may be mediated by the calcineurin pathway 
as. well. Thus, cyclosporine and tacrolimus binding pro-
tems are present at a high concentration in the kidney 
(higher than in the liver and spleen). Calcineurin immu-
noreactivity and enzyme activity in the kidney can be 
specifically inhibited by tacrolimus or cyclosporine but 
not by rapamycin. a drug that blocks a different cell 
signal involved in the T-cell proliferative response to 
interleukin-2 (12.13). At the cellular level, morphologic 
observations (reviewed subsequently) suggest that tubu-
lar epithelial cells. \'ascular endothelial cells, arteriolar 
myocytes, and interstitial fibroblasts are all targets for 
cyclosporine and tacrolimus nephrotoxicity. 
The occurrence of epithelial vacuolization in clinical 
biopsy material suggests a direct toxic effect of tacroli-
mus and cyclosporine on the renal tubule. The exact 
1at the diagnosis must be made by the process of ex-
Jusion. In allograft kidneys, it may be necessary to show 
n absence of acute rejection by biopsy, whereas in Iiver-
~ansplant patients, hepatorenal syndrome and hepatic 
:Iomerulopathies are considerations in the differential 
:iagnosis. Likewise. in heart and lung transplant recipi-
nts. atherosclerotic and hypertensive nephropathy need 
J be excluded before making a diagnosis of tacrolimus 
lephrotoxicity. The clinical diagnosis is most secure 
.,·hen there is a decrease in serum creatinine levels after 
1 reduction in tacrolimus dosage: however, chronic ta-
:rolirnus nephrotoxicity may be nonreversible (11,44) 
md. indeed, may not be detected unless routine moni-
:oring of serum creatinine is supplemented periodically 
oy creatinine clearance measurements. The distinction of 
.:hronic tacrolimus nephrotoxicity from insidiously de-
\eloping chronic rejection is difficult on clinical 
grounds. 
The temporal evolution of acute tacrolimus nephro-
toxicity and its response to reduction in drug dosage have 
been described. The baseline creatinine level in one se-
ries of 22 patients was 212.2 ± 168.0 fJ.moUL and 
showed a mean rise of ~MKSDit ± 1~KODit during episodes 
of nephrotox ici ty (-+8). Concurrent extrarenal manifesta-
tions of tacrolimus [Oxicity were relatively common: 
hyperkalemia was recorded in 41 'it cases. hyperglycemia 
in 36'it of previously nondiabetic patients, and hand 
tremors (neurotoxicity) in 9'it of subjects. The highest 
mean plasma and whole blood tacrolimus levels during 
the toxic episodes were 2.7 ± 0.8 ng/ml (normal range, 
0.5-1.5) and 31.6 ± 10.6 ng/ml (normal range. 5-20), 
respectively. Nephrotoxicity episodes were associated 
with elevated plasma or whole blood in tacrolimus levels 
in 82'it patients. In other studies. a correlation between 
blood tacrolimus levels and nephrotoxicity was observed 
by some authors (52-54) but nOl by others (45.55). The 
dose of tacrolimus was reduced stepwise in response to 
a diagnosis of tacrolimus nephrotoxicity until a satis-
factory response in serum creatinine was obtained. The 
mean dose reduction was 41 'it ± 21 'it (range. 11-89) and 
led to a 86'it ± l8'it (range. 45-100) decrease in the 
serum creatinine level (48). This variation in the per-
cent of dose reduction necessary to restore allograft func-
rion reflects the known variability of tacrolimus pharma-
cokinetics in individual patients (56). The drug kinetics 
can be altered further by hepatic dysfunction and a va-
riety of drug interactions. Thus. in patients receiving 
drugs that interfere with tacrolimus metabolism by the 
liver (itraconazole. erythromycin. diltiazem), drastic re-
ductions in tacrolimus dosage may be required to reverse 
tacrolimus nephrotoxicity, and clinical response is de-
layed. 
MORPHOLOGIC FINDINGS OF 
TACROLIMUS NEPHROTOXICITY 
A description of the principal morphologic findings 
found in renal allograft biopsies performed during clini-
cal episodes of tacrolimus nephrotoxicity follows. 
Functional toxicity 
Some patients on tacrolimus therapy develop labora-
tory evidence of graft dysfunction without remarkable 
morphological findings at biopsy. The renal dysfunction 
recovers as the dosage of tacrolimus is reduced. A simi-
lar phenomenon has been described with cyclosporine 
therapy and is believed to be the result of drug-induced 
vasospasm (57.58). 
Acute tubular necrosis 
Cyclosporine has been linked to the occurrence of 
acute tubular necrosis in the first several weeks after 
~rapsplantationK Acute tubular necrosis during this inter-
val can. of course. be due entirely to ischemic injury 
associated with the harvesting and implantation of the 
donor organ. There is experimental evidence. however, 
that immunosuppressive drugs can exaggerate such isch-
emic injury to the tubules (59). The frequency of acute 
renal failure and the duration of postoperative oliguria 
are greater in patients immunosuppressed with cyclo-
sporine than with azathioprine (60). These observations 
also may be applicable to tacrolimus-treated patients. as 
this drug could potentiate renal ischemia by causing va-
sospasm, but clinical studies confirming this have not yet 
been performed. 
Tubular vacuolization 
Biopsies performed during clinical episodes of tacro-
limus nephrotoxicity frequently show tubular vacuoliza-
tion. In our experience. these tubular vacuoles are seen in 
proximal as well as distal tubules (Fig. I). Although 
typically about equal in size and shape (isometric). focal 
coalescence into larger vacuoles is also demonstrable 
(61). The Japanese FK506 study group considers tacro-
Iimus therapy to cause a "rough and foamy" tubular 
vacuolation in the proximal tubules (62). CycIosporine 
toxicity is also associated with isometric tubular vacuol-
ization, which is described by some authors to be found 
almost exclusively in the straight part of the proximal 
convoluted tubules (57). Tubular vacuolization may be 
better appreciated on trichrome compared with routine 
hematoxylin and eosin stains (63). Ultrastructurally, the 
vacuoles reflect dilatations in the endoplasmic reticulum 
(Fig. 2); some contain proteinaceous material and re-
semble lysosomes (61.63). 
In addition to cyclosporine and tacrolimus toxicity. 
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FIG. 3. This afferent :uteriole from a patient with clinical tacrolimus 
nephrotoxicity shows myoc~le y·a~uolizationK Hyalin material can be 
seen deposited in the intima (penodic acid Schiff s stainl. 
curs in cardiac myocytes exposed to chemical. meta-
bolic. and ischemic injury 01-74). 
Tubular calcifications 
Focal microcalcification in the renal parenchyma has 
been described in experimental tacrolimus and cyclo-
sporine nephrotoxicity (75). Similar lesions occur in hu-
man biopsies (57.61) and. in some cases. may represent 
calcification of tubular epithelium damaged by these 
drugs; however. panicipants of one international work-
shop found the frequency of microcalcifications in pa-
tients on cyclosporine therapy to be comparable to that 
obsen'ed with azathioprine. a drug not considered neph-
rotoxic (66), The differential diagnosis includes dystro-
phic calcification at the site of prior ischemic or immu-
nologic tubular injury and. less commonly. calcification 
resulting from hypercalcemic states. such as renal hyper-
parathyroidism. 
Giant mitochrondria 
Giant mitochondria within the tubular epithelium have 
been demonstrated in tacrolimus-treated rats (59). We 
material, but literature IS a\all .. Ul<;; 0li '-) ~DsutDs""_ 
treated patients. Mihatsch et a1. described round, oval, or 
cigar-shaped mitochondria up to half the size of the 
nucleus (57). These inclusions are rare even in cases with 
severe toxicity, and usually only one giant organelle is 
found per cell. Giant mitochondria and isometric vacu-
olation are said never to be observed in the same cell. 
Electron microscopy is needed for definite differentia-
tion from phagolysosomes. The frequency of giant mi-
tochondria in patients on cycIosporine therapy is higher 
compared with conventional immunosuppressive drugs 
in some series (57) but not in others (60). Giant mito-
chondria are not specific for cyclosporine toxicity and 
have been described in ischemia, glomerulonephritis, 
systemic lupus erythematosus, minimal change nephrotic 
syndrome, and patients receiving azathioprine. 
Acute microvascular toxicity 
Renal allografts maintained on cycIosporine show 
scattered thrombi in the glomerular capillaries and arteri-
FIG. 4. Ultrasuucturally, myocyte vacuoles resemble tubular vacu-
oles in that they reflect a combination of dilated endoplasmic reticulum 
and lysosomes. 
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therapy: One showed peculiar eosinophilic globules in 
the media, and another showed rare subendothelial lym-
phocytes and focal medial necrosis (76). Other similar 
cases have been reponed from Japan and France (62,92). 
Differentiating these lesions from vascular rejection with 
intimal arteritis is both difficult and critical. The pres-
ence of significant lymphocytic infiltrates in the intima, 
scattered interstitial hemorrhages. tubuli tis, and diffuse 
global glomerulitis fayor the diagnosis of rejection over 
drug toxicity. 
Before leaving this subject. it is of interest to recalJ 
that the potential of tacrolimus to cause injury to blood 
yessels was much debated during the developmental 
phase of this drug. Vascular damage described as "vas-
culitis" involving medium-sized arteries in the liver. 
pancreas. and heart was reponed in tacrolimus-treated 
dogs (93). Work done by our colleagues and others 
raised doubts about the significance of these findings. as 
vasculitis was found with equal frequency in control ani-
mals (94.95). Studies in rats. baboons. and monkeys 
treated with tacrolimus (59.96) also were unable to re-
produce vasculitis lesions. Aneriolar-sized renal vessels 
in rats and dogs treated with tacrolimus develop focal 
medial necrosis. accumulation of eosinophilic inclusions. 
and juxtaglomerular transformation but not true arteritis 
(94.97.98). In our opinion. these arteriolar lesions are 
similar to those reponed with dopaminergic and adren-
ergic drugs and are adequately explained by intense va-
sospasm (99.100). 
Arteriolar h~Dalinosis 
Both cyclosporine and tacrolimus therapy are associ-
ated with hyaline eosinophilic deposits (Figs. 3 and 7) 
within the arterioles (57.61.101). Immunofluorescence 
examination shows these deposits to contain several pro-
teins including fibrin. immunoglobulin M. C3. and Clq. 
Hyalinosis is particularly seen in patients on prolonged 
drug therapy. but this change conceivably can develop 
rapidly after acute aneriolopathy. It is imponant to keep 
in mind that similar vascular changes can be seen as a 
result of aging. hypenension. and diabetes mellitus. 
which would explain why in some studies wherein cy-
closporine is used at low dosage or the follow-up is 
relatively shon. the incidence of hyalinosis is not signifi-
cantly higher than in control biopsies (102.103). A nodu-
lar configuration to the hyalin has been considered char-
acteristic of dru!:! toxicity (57), but this feature has also 
been described i~ donor:transmitted nephrosclerosis and 
in patients dying of ischemic cardiomyopathy (104.105). 
Even after re\'iew of clinical data and previous biopsies. 
it is not always possible to ascenain definitively the un-
derlying cause of hyalinosis in individual biopsies. and 
FIG. 7. Periodic acid Schiff (PAS)-stained section illustrating ane-
riolar hyaline change associated with tacrolimus therapy. The smaller 
of the two anerioles in this photomicrograph shows early hyalinosis 
confined to the intima. The larger aneriole shows transmural involve-
ment. affecting greater than half its circumference. with hyalin material 
also lying in the vascular lumen. 
sometimes mUltiple factors appear to be involved. Some 
authors find electron microscopy (Fig. 8) useful in this 
setting and state that in cyclosporine toxicity the hyaline 
deposits are circular and replace underlying necrotic 
smooth muscles. whereas in diabetes or hypertension. the 
deposits are not accompanied by degenerative or necro-
tizing changes in the myocytes (57). Other authors have 
been unable to find myocyte necrosis in cycJosporine-
associated aneriolar hyalinosis, however, possibly be-
cause they looked at biopsies at a later stage of the dis-
ease (102.106). Detailed ultrastructural evaluations of ta-
crolimus-associated hyalin change are not reponed in the 
literature. 
Striped fibrosis 
Prolonged use of cyclosporine and tacrolimus can 
cause interstitial fibrosis. which is said to have a 
"striped" pattern (57,61) resulting from areas of isch-
emic tubular atrophy and interstitial fibrosis alternating 
with relatively well-preserved or even hypenrophic renal 
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Glomerular pathology 
The occurrence of glomerular capillary and afferent 
aneriolar thrombosis as a manifestation of cyclosporine 
and tacrolimus nephrotoxicity has been mentioned ear-
lier (76-82). In cases with frank hemolytic uremic syn-
drome, clinical resolution can be complete, but residual 
injury in the form of glomerular capillary basement 
membrane thickening and duplic3tion may persist (109). 
Experimental studies show that ta:rolimus and cyclo-
sporine can cause juxtaglomerular hyperplasia, possibly 
by a local activation of the renin-angiotensin system 
(37.98). The diagnostic utility of this finding in clinical 
practice is limited because a study of the juxtaglomerular 
apparatus requires specialized histo:hemical techniques. 
Furthermore. juxtaglomerular apparatus hyperplasia is a 
nonspecific finding described in other clinical settings, 
such as rejection. arteriosclerosis. hypenension. and re-
flux nephropathy (110). 
The occurrence of focal segmental or global sclerosis 
is mentioned in the literature as one of the manifestations 
of chronic drug toxicity (102.111- I 13). It should be kept 
in mind. however. that focal segmental sclerosis is also a 
nonspecific lesion that may be observed in many dis-
eases. including chronic rejection. renal artery stenosis. 
recurrent glomerulonephritis. and reflux nephropathy. 
The pathogenesis in cases of drug-induced injury may 
reflect segmental ischemic collapse of the glomerular 
capillary loops secondary to the lesion of arteriolar hya-
linosis (57.61.101). Resolution of intraglomerular capil-
lary thrombosis could account for some cases (76.82). 
. -\ltemativeJy. the lesion could reflect a compensatory 
response to nephron loss caused by the vascular and 
interstitial effects of cycJosporine and tacrolimus. Thus, 
it is believed that compensatory glomerular hypertrophy 
can result in capillary hyperfiltration. endothelial injury. 
mesangial dysfunction. and progressh'e segmental or 
global glomerulosclerosis (114). A possible link between 
glomerulosclerosis and local activation of the renin an-
giotensin system is suggested by experiments demon-
strating stimulation of extracellular matrix protein syn-
thesis by rat glomerular mesangial cells exposed to an-
giotensin II (l15). Mesangial matrix protein synthesis 
also can be enhanced by TGF-I3. a c~1Mkine known to be 
stimulated by cyclosporine (40\. 
NATURAL HISTORY OF 
TACROLIMUS NEPHROTOXICITY 
Tacrolimus-induced tubular vacuolization. acute ane-
riolopathy, and thrombotic microangiopathy generally 
respond well to reduction in the drug dose; histologic 
improvement can be documented in follo\\'-up biop-
sies. Studies specifically addressing the question of 
whether chronic tacrolimus nephrotoxicity results in pro-
gressive graft loss have not yet been published; however, 
data are available showing that long-term graft survival 
in tacrolimus-treated patients is superior to that reported 
for cyclosporine and azathioprine (a drug not considered 
nephrotoxic) (10). Hence. it is unlikely that chronic ad-
ministration of tacrolimus is a frequent cause of graft 
loss. 
The natural history of tacrolimus-associated arteriolar 
hyalinosis and interstitial fibrosis needs to be defined by 
examination of sequential biopsies from renal transplant 
recipients. Uncontrolled studies on cyclosporine-treated 
patients suggest that discontinuation of the drug leads to 
resolution of mild arteriolar hyalin deposits in some 
cases but to continued accumulation in other patients 
(116,117). In evaluating such data, it should be kept in 
• rllind that arteriolar hyalin deposits can be extremely 
focal in distribution and may involve fewer than 10% of 
vessels sampled at biopsy (116), leading to difficulty in 
distinguishing between sampling artefact and true reso-
lution/progression of lesions in sequential biopsies (106). 
We have noted that striped fibrosis has a similar uneven 
distribution in renal allografts (61). 
SUMMARY 
A variety of renal lesions have been described in pa-
tients undergoing episodes of tacrolimus nephrotoxicity . 
Although helpful to the pathologist seeking morphologic 
clues to substantiate drug toxicity, none of these lesions 
is specific to the extent that it has not been reported in 
other conditions. This is not surprising because alI organs 
in the human body possess only a limited repenoire of 
tissue reactions to deal with injurious stimuli. The diag-
nosis of tacrolimus nephrotoxicity is therefore best made 
with reference to the clinical context and after exclusion 
of other causes of graft dysfunction. The ultimate con-
firmation is a decline in serum creatinine levels follow-
ing a reduction in tacrolimus dosage. Chronic tacrolimus 
nephrotoxicity can be nonreversible. however, and may 
be regarded as the "price to be paid" for maintaining 
continuous immunosuppression. Because the nephro-
toxic and antirejection actions of tacrolimus might be 
mechanistically related. it may not be possible to avoid 
tacrolimus nephrotoxicity altogether. Fortunately, there 
is evidence that the effects can be minimized by the use 
of low-dose regimens. Observed and projected long-term 
graft survivals with tacrolimus now equal or exceed 
those obtainable with alternative immunosuppressive 
drugs (10). 
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